Vaximm
Basel · Founded 2008
About Vaximm
Vaximm is focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Their initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. Vaximm has shown impressive anti-tumor activity in various animal studies and will enter first human clinical trials in 2011.
Company Facts
- Founded: 2008
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $8.0M
- Last round: Grant (Oct 2012)
- Website: https://vaximm.com
- Phone: + 49-0621-83-596-8750
Industries & Categories
Biotechnology, Developer Platform, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/vaximm-10320 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.